Blockchain Press Releases
Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets
CHICAGO, Aug. 18, 2023 /PRNewswire/ — In the near future, the Clinical Trial Imaging industry is poised to undergo a transformative evolution, driven by rapid advancements in medical imaging technology, data analytics, and regulatory frameworks. Cutting-edge imaging modalities such as functional MRI, molecular imaging, and advanced PET-CT scans will enable researchers to delve deeper into the intricacies of disease progression and treatment response, providing more nuanced and personalized insights. Integration of artificial intelligence and machine learning algorithms will streamline image analysis, facilitating quicker and more accurate diagnoses, patient stratification, and endpoint determination. Additionally, seamless collaboration between pharmaceutical companies, research institutions, and imaging facilities, coupled with standardized protocols, will enhance data sharing and accelerate clinical trial timelines. However, this expansion will also bring challenges in terms of data security, protocol harmonization, and ensuring the reliability of novel imaging techniques. In essence, the Clinical Trial Imaging industry’s imminent future promises to revolutionize the landscape of medical research, enhancing the efficiency and effectiveness of drug development while ultimately benefiting patient outcomes.
Clinical Trial Imaging Market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising expenditures in research and development, the expansion of the pharmaceutical and biotechnology sectors, and the proliferation of Contract Research Organizations (CROs) constitute several additional factors. Emerging economies like China, India, and Japan present attractive prospects for stakeholders engaged in the clinical trial imaging market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624
Browse in-depth TOC on “Clinical Trial Imaging Market”
111 – Tables
38 – Figures
179 – Pages
Clinical Trial Imaging Market Scope:
|
Report Coverage |
Details |
|
Market Revenue in 2023 |
$1.3 billion |
|
Estimated Value by 2028 |
$1.9 billion |
|
Growth Rate |
Poised to grow at a CAGR of 7.8% |
|
Market Size Available for |
2021–2028 |
|
Forecast Period |
2023–2028 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Service & software, modality, therapeutic area, end user and region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Report Highlights |
Updated financial information / product portfolio of players |
|
Key Market Opportunities |
Growth opportunities in emerging economies |
|
Key Market Drivers |
Rise in research and development expenditures |
The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
Based on product, the clinical trial imaging market is segmented into services and software. In 2022, services accounted for the largest share of the global clinical trial imaging market. The large share of this segment can primarily be attributed to the high cost of imaging equipment, which has driven the outsourcing of imaging clinical trials by pharmaceutical, biotechnology, and medical device manufacturers to service providers.
Positron emission tomography segment to register the highest growth rate during the forecast period
The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities. In 2022, the positron emission tomography segment accounted for the highest growth rate. Technological expansions and the introduction of new tracers for cardiology, oncology, and neurology applications are expected to support the adoption of PET systems in clinical trial settings.
The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area. In 2022, the oncology segment accounted for the largest share of the clinical trial imaging market. The dominant portion of this segment’s market share can be chiefly attributed to the extensive volume of oncology-related clinical trials, driven by the global increase in cancer incidence.
North America is the largest regional market for clinical trial imaging market
The global clinical trial imaging market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the clinical trial imaging market. The large share of this region can be attributed to the growing cutting-edge medical technologies, a mounting count of pharmaceutical and biotechnology enterprises, and substantial governmental investments in clinical research and development.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30446624
Clinical Trial Imaging Market Dynamics:
Drivers:
- Increasing R&D spending
- Growth of pharmaceutical and biotechnology industries
- Increasing number of CROs
Restraints:
- High implementation cost of imaging systems
Opportunities:
- Growth opportunities in emerging economies
- Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
Challenges:
- High cost of clinical trials
Key Market Players:
The major players operating in this market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Recent Developments:
- In March 2023, ICON Plc. (Ireland) announced a strategic partnership with LEO Pharma (Denmark) to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
- In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials.
- In May 2021 IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=30446624
Clinical Trial Imaging Market Advantages:
- Enhanced Decision Making: Imaging technologies allow researchers and clinicians to visualize biological processes and disease progression in real-time. This enables more informed decision-making during clinical trials by providing objective and quantifiable data on treatment efficacy and safety.
- Early Endpoint Identification: Imaging enables the identification of early treatment responses and disease progression markers, enabling the early determination of trial endpoints. This leads to quicker assessment of treatment outcomes and potential for adaptive trial designs.
- Patient-Centric Approach: Imaging modalities like PET scans, MRIs, and CT scans provide a non-invasive way to monitor patient health, reducing the need for invasive procedures. This patient-centric approach improves participant comfort and compliance in clinical trials.
- Personalized Medicine: Advanced imaging techniques facilitate the identification of patient subgroups that respond better to specific treatments. This leads to the development of targeted therapies, enhancing treatment effectiveness and minimizing adverse effects.
- Efficient Drug Development: Imaging accelerates drug development by providing insights into a drug’s mechanism of action and its impact on disease pathways. This reduces the time and costs associated with traditional trial endpoints, contributing to faster market entry for new drugs.
- Objective Quantification: Imaging offers objective measurements of treatment effects, reducing subjectivity in data interpretation. This improves the robustness and credibility of trial results, enhancing the likelihood of regulatory approval.
- Global Collaboration: Digital imaging technology allows real-time sharing of data across geographical boundaries, facilitating collaboration among researchers, clinicians, and regulatory agencies. This leads to standardized protocols and increased harmonization across clinical trials.
- Regulatory Compliance: Well-established imaging techniques adhere to rigorous regulatory standards, ensuring the safety and ethical considerations of participants. This instills confidence in trial outcomes and supports regulatory approval processes.
- Longitudinal Monitoring: Imaging enables researchers to track disease progression and treatment response over time, providing insights into the long-term effects of interventions. This information is crucial for understanding chronic diseases and evaluating treatment durability.
- Translational Research: Clinical trial imaging bridges the gap between preclinical research and human studies, allowing researchers to validate findings in real-world patient populations. This aids in the translation of promising preclinical discoveries into effective clinical interventions.
In summary, the advantages of the Clinical Trial Imaging market lie in its ability to provide objective, precise, and timely data, enhancing the efficiency and success rate of drug development while ultimately benefiting patient care and medical advancements.
Related Reports:
CRO Services Market – Global Forecasts to 2028
Mice Model Market – Global Forecasts to 2028
Clinical Trial Supplies Market – Global Forecasts to 2028
Contrast Media Market – Global Forecasts to 2027
Diagnostic Imaging Market – Global Forecasts to 2026
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/clinical-trials-imaging-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/clinical-trials-imaging.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-imaging-market-worth-1-9-billion–marketsandmarkets-301904364.html
Blockchain Press Releases
MEXC Announces Listing of Hyperlane (HYPER) with a 165,000 HYPER and 50,000 USDT Prize Pool
VICTORIA, Seychelles, April 21, 2025 /PRNewswire/ — MEXC, a leading global cryptocurrency exchange, announced the Hyperlane (HYPER) listing on April 22, 2025(UTC).To celebrate this significant addition to the exchange, MEXC is launching a special event with a prize pool of 165,000 HYPER and 50,000 USDT for new and existing users.
Hyperlane is the first permissionless, universal interoperability protocol dedicated to building a truly open and decentralized cross-chain communication infrastructure. As “The Open Interoperability Framework,” it enables anyone to freely expand, utilize, and customize the network, allowing developers to easily and securely build cross-chain applications and token bridges. To date, Hyperlane has connected over 140 blockchains, processed nearly 9 million cross-chain messages, and bridged more than $6 billion in volume through its Warp Routes.
$HYPER is the native token of the Hyperlane ecosystem, with an initial total supply of 1 billion tokens. It plays a critical role in securing the protocol through staking, rewarding validators for verifying cross-chain messages, incentivizing user-driven activity, and enabling community governance over protocol development.
To celebrate the listing, MEXC will launch an Airdrop+ event with substantial rewards for users:
Event Period: April 21, 2025, 10:00 – May 01, 2025, 10:00 (UTC)
Benefit 1: Deposit and share 120,000 HYPER (New user exclusive)
Benefit 2: Spot Challenge — Trade to share 15,000 HYPER (For all users)
Benefit 3: Futures Challenge — Trade to share 50,000 USDT in Futures bonus (For all users)
Benefit 4: Invite new users and share 30,000 HYPER (For all users)
MEXC has established itself as a leading exchange by consistently offering users early access to high-potential crypto assets. In 2024 alone, the platform listed 2,376 new tokens, including 1,716 initial listings. According to the latest TokenInsight report, MEXC led the industry with 461 spot listings between November 1, 2024, and February 15, 2025. During this period, the exchange maintained a high listing frequency, consistently ranking among the top six platforms, demonstrating its agility in capturing emerging market trends. MEXC will continue to expand its asset offerings and help users seize timely opportunities in the fast-moving crypto market.
For full event details and participation rules, please visit here.
About MEXC
Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 36 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
Risk Disclaimer:
The information provided in this article regarding cryptocurrencies does not constitute investment advice. Given the highly volatile nature of the cryptocurrency market, investors are encouraged to carefully assess market fluctuations, the fundamentals of projects, and potential financial risks before making any trading decisions.
Photo – https://mma.prnewswire.com/media/2668781/1920×1080.jpg
Logo – https://mma.prnewswire.com/media/2668118/MEXC_new_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mexc-announces-listing-of-hyperlane-hyper-with-a-165-000-hyper-and-50-000-usdt-prize-pool-302433327.html
Blockchain Press Releases
Introducing Clementine Bridge: Citrea Deploys First Complete BitVM Bridge Design on Testnet
Citrea’s Clementine Bridge marks the first time that a fully programmable layer is tested for settling on Bitcoin.
GEORGE TOWN, Cayman Islands, April 21, 2025 /PRNewswire/ — Citrea, the first ZK rollup to enhance capabilities of Bitcoin blockspace and enable Bitcoin applications (₿apps), has successfully deployed its Clementine Bridge, the first complete BitVM bridge design on Bitcoin Testnet. Citrea has also recently revealed Clementine’s whitepaper, marking the first real-world implementation of a BitVM-based bridge which extends BTC’s utility to decentralized finance in the most Bitcoin-secured and native way possible. With Clementine’s testnet deployment, Bitcoin is for the first time tested for optimistically verifying a fully programmable layer. The Clementine whitepaper is currently the only documentation of how to use BitVM in a bridge design with clear solutions toward a secure and efficient bridge implementation.
Despite being the world’s largest digital asset, BTC has struggled to build relevance in decentralized finance. A secure bridge between Bitcoin and a secondary layer has always been a bottleneck for using BTC in a programmable environment. This problem has forced users to either keep Bitcoin as a passive store of value or rely on custodians for using BTC in financial activities. Citrea’s BitVM-based Bitcoin bridge Clementine solves this by enabling the safest and most trust-minimized way to bridge BTC and extend its utility to decentralized finance.
Citrea’s Clementine bridge marks a historic moment for Bitcoin and a new beginning for BTC’s utility. “It felt like magic when we saw all the bridge components work smoothly in our internal tests and that any malicious act is stopped by a single honest actor,” said Ekrem Bal, Co-Creator of Citrea. “We’re now ready to test Clementine in a real Bitcoin Testnet environment and make it more battle-tested for Citrea mainnet.”
With the introduction of BitVM by a Bitcoin developer Robin Linus, verifying computations on Bitcoin and building Bitcoin-secured bridges became a possibility. Very soon after its introduction, Citrea team became a core contributor of BitVM and later a founding member of BitVM alliance, where BitVM’s fundamental technology of executing a fraud proof of a zero-knowledge (ZK) proof on Bitcoin was developed collaboratively. Although accomplishing a ZK proof verification on Bitcoin was a prerequisite, there were still critical problems to address to implement this fundamental technology securely and efficiently into a Bitcoin bridge design. A detailed breakdown of this can be found in Clementine’s whitepaper.
Clementine’s design and whitepaper introduce novel solutions to two main research topics in BitVM-based bridge implementation, namely Bitcoin chain fork selection and capital efficiency of operators. These topics have been critical to solve as they ensure both the bridge’s security and efficiency. Citrea’s Clementine bridge offers clear solutions to both of these problems:
- Bitcoin Chain Fork Selection: This is related to ensuring that the bridge follows the longest Bitcoin chain. It has been an open research topic where the BitVM creator introduced superblocks approach but its security was later found to be broken. Citrea introduces a new Bitcoin Light Client design that uses succinct Header Chain Proofs of Bitcoin. These proofs are aggregated by operators into a single BitVM proof.
- Capital Efficiency of Operators: This has been another limitation of implementing BitVM efficiently into a bridge design. With Citrea’s approach to non-standard Bitcoin transactions, operators can now process hundreds of withdrawals in parallel with a single collateral. Disproving only one withdrawal is enough to stop other malicious withdrawal processes.
Clementine’s design relies on zero-knowledge proofs, Bitcoin data availability, a novel Bitcoin Light Client design and BitVM. In the case of a malicious act, an honest watchtower provides a proof of the longest Bitcoin chain. Then the operator generates a proof verifying Citrea’s state, watchtowers’ challenges and payout for the withdrawal. If the operator is malicious, it won’t be able to generate such proof, resulting in slashing the operator. Clementine has three main bridge actors to ensure the system’s integrity:
- Signers enforce BitVM spendings by managing peg-ins through presign transactions
- Watchtowers are tasked with monitoring operators and challenging any malicious behavior by sending a proof of longest Bitcoin chain
- Operators, a group of profit-seeking entities, temporarily cover users’ withdrawals and are later reimbursed with presigned transactions.
Citrea: Bitcoin’s Application (₿app) Layer
Citrea extends Bitcoin’s utility without sacrificing its security. With zero-knowledge technology, Citrea enables Bitcoin to function as a fully programmable layer. With its Bitcoin bridge Clementine, Citrea offers the safest and most trust-minimized way to bridge BTC to a fully programmable secondary layer.
For the first time in its history, Bitcoin Network will be able to support diverse on-chain applications and its utility will be extended to decentralized finance.
Apply to Citrea’s unique incubation program ‘Citrea Origins‘ to build ₿apps.
For more information, please visit: Citrea website | Citrea X Account
View original content:https://www.prnewswire.co.uk/news-releases/introducing-clementine-bridge-citrea-deploys-first-complete-bitvm-bridge-design-on-testnet-302432655.html
PANAMA CITY, April 21, 2025 /PRNewswire/ — BingX, a global leading cryptocurrency exchange, announces the listing of EPT, the native token for Balance.fun, for both spot trading and also on the BingX Xpool. The spot listing will commence on April 21 at 12:00 (UTC) while the Xpool launch will start on April 22 at 10:00 (UTC). BingX users can stake BTC and EPT in Xpool, though new users will have an additional option to stake USDT to win a bigger share of the reward pool that includes 2,000,000 EPT Points. The first 1000 new users who stake a minimum of 100 USDT will also be able to earn an additional bonus voucher worth 100 USDT.
EPT is the governance token of Balance, an AI-powered web3 experience infrastructure designed for the masses. This new digital asset will fuel the new Balance Platform to create an open and inclusive gaming ecosystem for both gamers and developers with fairness at its core. With the integration of AI and blockchain technology, games can be built and marketed more easily while allowing players to benefit from the enhanced and diversified gaming experience.
Users of the existing Epal platform can transfer their EPT tokens to BingX, enabling a reliable method to trade EPT or, alternatively, purchase EPT for governance purposes. Having a solid exchange to further explore the vast world of cryptocurrencies, this new listing further empowers both Epal and Balance users in the process.
Vivien Lin, Chief Product Officer of BingX, shared her thoughts on the new trading option and Xpool listing: “I think providing users with these new trading and early investment options is our responsibility as a responsible cryptocurrency exchange since some of our users rely on us to introduce such projects with such numerous functions across multiple subcategories”.
Visit bingx.com to join the Xpool starting April 22 and start trading EPT on spot from April 21. Whether you’re a gamer, builder, or crypto enthusiast, this is your chance to be part of a new decentralized chapter in entertainment.
About BingX
Founded in 2018, BingX is a leading crypto exchange, serving over 20 million users worldwide. BingX offers diversified products and services, including spot, derivatives, copy trading, and asset management – all designed for the evolving needs of users, from beginners to professionals. BingX is committed to providing a trustworthy platform that empowers users with innovative tools and features to elevate their trading proficiency. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports.
For more information, please visit: https://bingx.com/
Photo – https://mma.prnewswire.com/media/2668931/BINGX.jpg
Logo – https://mma.prnewswire.com/media/2310183/BingX_logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bingx-brings-balance-ept-to-spot-with-a-200-million-ept-xpool-302433296.html
-
Blockchain Press Releases5 days agoHTX Completes Fireblocks Off-Exchange Integration, Advancing Institutional Trading Security and Efficiency
-
Blockchain Press Releases6 days ago
BTC Puts at 2023 Crisis Levels Amidst Tariff Storm: New Bybit x Block Scholes Crypto Derivatives Report
-
Blockchain5 days ago
Good Game Reality Show Reimagines Global Gaming Stardom with Tokenized Memberships and Real-Life Lounges
-
Blockchain6 days agoBlocks & Headlines: Today in Blockchain – April 15, 2025 | JPMorgan, Signing Day Sports, Moreno, Russia Global Forum, Kalp Studio
-
Blockchain5 days ago
Fifth Era Acquisition Corp I Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing April 21, 2025
-
Blockchain3 days ago
Relm Insurance and Liva Insurance Obtain Central Bank Approval in the UAE for Web3 Insurance Solutions
-
Blockchain7 days ago
Blocks & Headlines: Today in Blockchain – April 14, 2025: Featuring OM, XRP, JPMorgan, and Next-Gen Blockchain Innovations
-
Blockchain5 days ago
Blocks & Headlines: Today in Blockchain – April 16, 2025 – Featuring XYO, Solx, JP Morgan, Fuse, and Bybit
